| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
MLAB Stock Overview
Mesa Laboratories, Inc. designs, manufactures, and markets quality control instruments and disposable products in the United States, Europe, Asia, North America, and internationally.
Mesa Laboratories Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$299.25 |
| 52 Week High | US$333.42 |
| 52 Week Low | US$232.88 |
| Beta | 0.35 |
| 1 Month Change | -6.99% |
| 3 Month Change | -1.24% |
| 1 Year Change | 2.20% |
| 3 Year Change | 37.10% |
| 5 Year Change | 147.64% |
| Change since IPO | 9,671.43% |
Recent News & Updates
We Think Mesa Laboratories (NASDAQ:MLAB) Can Stay On Top Of Its Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Shareholder Returns
| MLAB | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0.1% | -4.8% | -4.6% |
| 1Y | 2.2% | -0.4% | 7.7% |
Return vs Industry: MLAB exceeded the US Medical Equipment industry which returned 0.8% over the past year.
Return vs Market: MLAB underperformed the US Market which returned 10.2% over the past year.
Price Volatility
| MLAB volatility | |
|---|---|
| MLAB Average Weekly Movement | 3.2% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 2.4% |
Stable Share Price: MLAB is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: MLAB's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1982 | 506 | Gary Owens | https://www.mesalabs.com |
Mesa Laboratories, Inc. designs, manufactures, and markets quality control instruments and disposable products in the United States, Europe, Asia, North America, and internationally. The company’s Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry.
Mesa Laboratories Fundamentals Summary
| MLAB fundamental statistics | |
|---|---|
| Market Cap | US$1.56b |
| Earnings (TTM) | US$5.09m |
| Revenue (TTM) | US$142.90m |
307.0x
P/E Ratio10.9x
P/S RatioIs MLAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MLAB income statement (TTM) | |
|---|---|
| Revenue | US$142.90m |
| Cost of Revenue | US$52.59m |
| Gross Profit | US$90.30m |
| Expenses | US$85.21m |
| Earnings | US$5.09m |
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.97 |
| Gross Margin | 63.20% |
| Net Profit Margin | 3.56% |
| Debt/Equity Ratio | 42.3% |
How did MLAB perform over the long term?
See historical performance and comparisonDividends
0.2%
Current Dividend Yield65%
Payout RatioDoes MLAB pay a reliable dividends?
See MLAB dividend history and benchmarks| Mesa Laboratories dividend dates | |
|---|---|
| Ex Dividend Date | Feb 25 2022 |
| Dividend Pay Date | Mar 15 2022 |
| Days until Ex dividend | 36 days |
| Days until Dividend pay date | 54 days |
Does MLAB pay a reliable dividends?
See MLAB dividend history and benchmarksValuation
Is Mesa Laboratories undervalued compared to its fair value and its price relative to the market?
307.02x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: MLAB ($299.25) is trading above our estimate of fair value ($213.28)
Significantly Below Fair Value: MLAB is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: MLAB is poor value based on its PE Ratio (307x) compared to the US Medical Equipment industry average (46.7x).
PE vs Market: MLAB is poor value based on its PE Ratio (307x) compared to the US market (17x).
Price to Earnings Growth Ratio
PEG Ratio: MLAB is poor value based on its PEG Ratio (8.7x)
Price to Book Ratio
PB vs Industry: MLAB is overvalued based on its PB Ratio (3.9x) compared to the US Medical Equipment industry average (3.5x).
Future Growth
How is Mesa Laboratories forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
35.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MLAB's forecast earnings growth (35.2% per year) is above the savings rate (2%).
Earnings vs Market: MLAB's earnings (35.2% per year) are forecast to grow faster than the US market (13% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: MLAB's revenue (11.8% per year) is forecast to grow faster than the US market (9.2% per year).
High Growth Revenue: MLAB's revenue (11.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MLAB's Return on Equity is forecast to be low in 3 years time (10.9%).
Past Performance
How has Mesa Laboratories performed over the past 5 years?
-25.7%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MLAB has high quality earnings.
Growing Profit Margin: MLAB became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: MLAB's earnings have declined by 25.7% per year over the past 5 years.
Accelerating Growth: MLAB has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: MLAB has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (51.2%).
Return on Equity
High ROE: MLAB's Return on Equity (1.3%) is considered low.
Financial Health
How is Mesa Laboratories's financial position?
Financial Position Analysis
Short Term Liabilities: MLAB's short term assets ($319.4M) exceed its short term liabilities ($28.7M).
Long Term Liabilities: MLAB's short term assets ($319.4M) exceed its long term liabilities ($181.0M).
Debt to Equity History and Analysis
Debt Level: MLAB has more cash than its total debt.
Reducing Debt: MLAB's debt to equity ratio has reduced from 58.4% to 42.3% over the past 5 years.
Debt Coverage: MLAB's debt is well covered by operating cash flow (22.8%).
Interest Coverage: MLAB's interest payments on its debt are not well covered by EBIT (2x coverage).
Balance Sheet
Dividend
What is Mesa Laboratories's current dividend yield, its reliability and sustainability?
0.21%
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: MLAB's dividend (0.21%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.35%).
High Dividend: MLAB's dividend (0.21%) is low compared to the top 25% of dividend payers in the US market (3.48%).
Stability and Growth of Payments
Stable Dividend: MLAB is not paying a notable dividend for the US market, therefore no need to check if payments are stable.
Growing Dividend: MLAB is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: MLAB is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MLAB's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
4.3yrs
Average management tenure
CEO
Gary Owens (53 yo)
4.33yrs
Tenure
US$2,557,718
Compensation
Mr. Gary M. Owens has been Chief Executive Officer, President and Director of Mesa Laboratories, Inc. since September 1, 2017. Mr. Owens joined as Chief Operating Officer in March 2017. Mr. Owens served as...
CEO Compensation Analysis
Compensation vs Market: Gary's total compensation ($USD2.56M) is below average for companies of similar size in the US market ($USD3.70M).
Compensation vs Earnings: Gary's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: MLAB's management team is considered experienced (4.3 years average tenure).
Board Members
Experienced Board: MLAB's board of directors are considered experienced (5.5 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: MLAB insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.1%.
Top Shareholders
Company Information
Mesa Laboratories, Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: Mesa Laboratories, Inc.
- Ticker: MLAB
- Exchange: NasdaqGS
- Founded: 1982
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$1.564b
- Shares outstanding: 5.23m
- Website: https://www.mesalabs.com
Number of Employees
Location
- Mesa Laboratories, Inc.
- 12100 West Sixth Avenue
- Lakewood
- Colorado
- 80228
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/01/19 23:34 |
| End of Day Share Price | 2022/01/19 00:00 |
| Earnings | 2021/09/30 |
| Annual Earnings | 2021/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.